Core Insights - TOMI Environmental Solutions, Inc. has appointed Mr. Harold W. Paul to its Board of Directors, effective immediately, succeeding Ms. Kelly J. Anderson who resigned as of September 30, 2025 [1][3] Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination through its Binary Ionization Technology (BIT) platform, marketed under the SteraMist brand [1][4] - The BIT solution utilizes a low percentage of hydrogen peroxide as its active ingredient and employs patented ionized Hydrogen Peroxide (iHP) technology for superior disinfection [4] Leadership Experience - Mr. Paul brings over 40 years of legal and securities expertise, along with extensive board leadership experience across various industries, having previously served on TOMI's Board from 2009 to 2021 [2] - He has advised numerous publicly traded companies as outside legal counsel and has served on the boards of six public companies [2] Strategic Importance - The CEO of TOMI, Dr. Halden Shane, expressed that Mr. Paul's knowledge of securities law and corporate governance will provide valuable insights as the company advances its strategy and expands its impact in critical industries [3]

Core Insights - TOMI Environmental Solutions, Inc. has made a strategic move by purchasing SteraMist iHP equipment and BIT Solution worth $175,000 through T.A.C.T. franchises, marking a significant step in its commercial growth strategy [1][2][3] Group 1: Company Developments - The phased rollout of SteraMist technology by T.A.C.T. franchises indicates their confidence in its effectiveness, with initial purchases leading to widespread adoption across all participating franchises [2][3] - The integration of SteraMist iHP technology into T.A.C.T.'s operations has been seamless, supported by TOMI's customer service and educational initiatives [3][5] - The partnership with T.A.C.T. is expected to create recurring revenue opportunities for TOMI, particularly through the BIT Solution [6] Group 2: Market Opportunities - There is a growing market opportunity in addressing mycotoxin contamination, which has reportedly increased by 20-30% in the U.S. over the past decade due to various environmental factors [5] - Mycotoxins pose significant health risks and can lead to costly consequences for businesses, making SteraMist iHP technology a valuable solution for remediation [5][6] - TOMI's SteraMist technology is positioned to tackle critical challenges in public health, particularly in commercial settings where mold and mycotoxin contamination are prevalent [6]

Core Insights - TOMI Environmental Solutions, Inc. has formed a strategic alliance with Steri-Clean to enhance its franchise-focused growth strategy and address increasing biohazard challenges in the U.S. [1] - The adoption of SteraMist iHP technology by Steri-Clean aims to improve service offerings in hoarding cleanup and biohazard remediation, leveraging advanced disinfection solutions [1][2] - Steri-Clean operates approximately 60 franchises and is recognized for its expertise in handling complex cleaning scenarios, including severe clutter and hazardous materials [2] - The initial implementation of SteraPak units at Steri-Clean's franchise locations is expected to enhance service efficiency and effectiveness in disinfection [3] - The partnership aligns with TOMI's broader commercial strategy, which includes educational initiatives and customer support enhancements to tackle emerging public health issues [4] Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination solutions, utilizing its Binary Ionization Technology® (BIT™) platform [4] - The BIT™ solution employs a low percentage of hydrogen peroxide as its active ingredient, utilizing patented ionized Hydrogen Peroxide (iHP™) technology for superior disinfection [4] - TOMI's products are designed for a wide range of applications, including hospitals, biosafety labs, commercial buildings, and emergency services [4]

Core Insights - TOMI Environmental Solutions, Inc. has announced a new service provider that will utilize its SteraMist iHP technology for mold and mycotoxins remediation in the healthcare sector, with an investment of approximately $185,500 in SteraMist mobile systems and BIT solution [1] - The new provider has secured a significant contract to remediate a 400,000-cubic-feet space at a hospital, which includes HVAC decontamination [1] - The partnership is expected to enhance TOMI's presence in the healthcare industry, leveraging the expertise of the new provider and its relationship with Enviro-Mist Inc., a long-standing partner specializing in mold remediation [2] Company Overview - TOMI Environmental Solutions, Inc. is a global company focused on decontamination and infection prevention, offering environmental solutions through its Binary Ionization Technology (BIT) platform [3] - BIT solution, developed under a defense grant with DARPA, utilizes a low percentage of hydrogen peroxide as its active ingredient and employs patented ionized Hydrogen Peroxide (iHP) technology for superior disinfection [3] - TOMI's products are applicable in various settings, including hospitals, biosafety labs, pharmaceutical facilities, and commercial buildings [3]

Core Insights - The U.S. FDA has expanded the permitted use of hydrogen peroxide as a secondary direct food additive, which presents growth opportunities for TOMI Environmental Solutions in the food industry [1][2][4] Company Overview - TOMI Environmental Solutions specializes in disinfection and decontamination solutions, utilizing its proprietary Binary Ionization Technology (BIT) platform, which employs food-grade hydrogen peroxide as its active ingredient [1][4] - The company's SteraMist technology is designed to ensure no detectable residues remain on food products, aligning with the new FDA regulations [3][4] Regulatory Changes - The FDA's new rule allows food-grade hydrogen peroxide that meets Food Chemicals Codex specifications to be used in food production, provided that any residues are removed before reaching consumers [2][4] - This regulatory change validates the safety and efficacy of TOMI's SteraMist iHP technology, which has been supported by scientific studies demonstrating rapid decomposition of hydrogen peroxide residues on treated produce [4] Market Opportunities - The updated FDA regulation opens various market verticals for TOMI, including food safety, transportation, storage, packaging, and pathogen reduction, enhancing food safety and extending the shelf life of food products [4]

Financial Data and Key Metrics Changes - The company reported a 40% increase in consumables revenue for 2025 compared to 2024, with a gross margin of approximately 60% [12] - Revenue growth over pre-COVID levels is at 38%, with product revenue and service revenue both showing growth [27][28] - Service revenue grew over 30% year over year, with a significant contribution from the life sciences and pharmaceutical sectors [36][29] Business Line Data and Key Metrics Changes - The company operates five divisions: biotechnology, food and beverage, commercial services, healthcare, and custom integration, each showing potential for growth [8][9] - The integrated mobile and service pipeline is around $21 million, with $7 million in active specific designs [33][29] Market Data and Key Metrics Changes - The market opportunity for the company's products spans billions in biotechnology, food and beverage, commercial services, and healthcare [7] - The global medical device market is valued at approximately $23.78 billion, growing at a CAGR of about 10% [41] Company Strategy and Development Direction - The company aims to capitalize on the shift away from ethylene oxide in the life sciences market, which presents a significant opportunity for growth [19] - The focus is on expanding service offerings and enhancing the sales team to address new applications of their technology [31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the conversion of open opportunities, citing a strong pipeline and ongoing contracts [37] - The company is optimistic about the lifting of capital restraints and the growing interest in their products post-COVID [20] Other Important Information - The company has 32 granted patents and over 200 trademarks registered in 50 states and more than 30 countries [7] - Recent FDA rule changes broaden the permitted use of hydrogen peroxide, opening new market opportunities in food safety and production [40] Q&A Session Summary Question: How repeatable is the growth in service revenue, and which industries are driving it? - Management indicated that the most traction is in life sciences and pharmaceuticals, with contracts for service revenue expected to grow year over year [36] Question: What gives confidence in conversion time and win rates? - Management noted that many opportunities are already won, and the design process with clients can take time, but they are confident in conversion rates [37] Question: How effective is the system at decontaminating facilities exposed to measles, and can production ramp up? - The company can quickly ramp up production using their backpack system, depending on capital availability [39]

Core Insights - TOMI Environmental Solutions, Inc. is participating in the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16 and 17, 2025, with a presentation by CEO Dr. Halden Shane [1] - The company specializes in disinfection and decontamination through its Binary Ionization Technology (BIT) platform, marketed under the SteraMist brand [4] Company Overview - TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) focuses on providing environmental solutions for disinfection, utilizing its BIT platform, which was developed with the Defense Advanced Research Projects Agency (DARPA) [4] - The BIT solution employs a low percentage of hydrogen peroxide as its active ingredient, utilizing patented ionized Hydrogen Peroxide (iHP) technology for superior disinfection [4] - TOMI's products cater to a wide range of sectors, including hospitals, biosafety labs, pharmaceutical facilities, commercial buildings, schools, and emergency services [4] Conference Details - The live webcast of TOMI's presentation will be available online, with a replay accessible afterward [2] - The iAccess Alpha conference features companies recommended by investors, providing opportunities for one-on-one meetings with TOMI [3]

Core Insights - TOMI Environmental Solutions, Inc. will participate in the H.C. Wainwright 25th Annual Global Investment Conference from September 8-10, 2025, in New York City [1][2] Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination through its Binary Ionization Technology (BIT) platform, marketed under the SteraMist brand [3] - The BIT solution utilizes a low percentage of hydrogen peroxide as its active ingredient and incorporates patented ionized Hydrogen Peroxide (iHP) technology for superior disinfection [3] - TOMI's products are applicable in various environments, including hospitals, biosafety labs, pharmaceutical facilities, schools, and commercial buildings [3]

Financial Data and Key Metrics Changes - In Q2 2025, total recognized revenue was approximately $1,000,000, a decline of 66% from $3,000,000 in Q2 2024, primarily due to customers deferring capital expenditure projects [14] - Service revenue for the quarter was $378,000, representing a 33% increase year-over-year, while service revenue for the first six months reached $955,000, a 299% increase [15] - Gross margin improved to 66% in Q2 2025, up from 62% in the same quarter last year, attributed to a favorable product mix [15] Business Line Data and Key Metrics Changes - Service revenue from IHP service deployments and validation support services grew by 33% compared to the same period last year and by 46% over the first six months [8] - BIT solution sales saw a 40% increase year-to-date, with expectations for continued growth due to repeat orders [10] - The company has a sales order backlog of approximately $4,600,000, with active projects scheduled for delivery in 2025 [7] Market Data and Key Metrics Changes - The company is negotiating approximately $2,000,000 in new custom and integrated contracts, with bids expected to close before year-end [7] - Open opportunities for three product offerings total approximately $15,000,000, with $7,000,000 designated as high priority [7] - The USDA increased its usage of SteraMist in Q2 2025, indicating growing market acceptance [12] Company Strategy and Development Direction - The company is focused on expanding customer outreach through targeted marketing strategies and strategic partnerships [9] - There is an emphasis on educating the market about proactive disinfection through the SteriMist Pro certified program [10] - The company aims to enhance its infrastructure by strengthening personnel in management and expanding its global distributor network [28] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about maintaining a positive trajectory for the remainder of 2025, despite challenges faced in Q2 [6] - The company anticipates significant orders from large companies as new manufacturing plants are built in the U.S. [38] - Management is hopeful that upcoming regulatory approvals will significantly impact growth [29] Other Important Information - The company was recognized as the Disinfection, Decontamination, and Disinfection Product Company of the Year for 2025 [12] - The company is developing a scalable solution to replace outdated methods in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases [21] - There is a strong pipeline of international partnerships in Europe, with pending approvals expected soon [23] Q&A Session Summary Question: Can you provide margins realized in solution sales compared to the rest of the business? - Management expressed excitement about solution sales, noting high margins and an increase in gross margins to 66% this quarter [33] Question: What opportunities arise from the strategy to bring back pharma manufacturing to the U.S.? - Management highlighted that high regulatory standards present opportunities for significant orders from large companies as new facilities are built [38] Question: Have any customers that deferred CapEx projects notified you about moving ahead? - Management indicated a significant increase in customer deposits and confirmed that at least two customers are expected to proceed with projects in 2026 [41] Question: Can you describe how SteraMist would be used if FDA approvals are obtained? - Management detailed ongoing FDA approval processes for medical devices and food safety applications, emphasizing the potential for expanded market opportunities [43][44] Question: Any new uses developed for SteraMist? - Management mentioned ongoing internal tests for new applications, including extending the shelf life of flowers, but noted hurdles to overcome before entering new industries [46]

Financial Results - For Q2 2025, net sales were $1,031,000, a decrease from $3,013,000 in Q2 2024, reflecting a decline in product sales due to deferred capital expenditures by customers [5][22] - For the first half of 2025, net sales were $2,608,000, down from $4,127,000 in the same period of 2024 [5][22] - Gross profit margin improved to 66% in Q2 2025, compared to 62% in Q2 2024, attributed to a favorable product mix [5][22] - The company reported an operating loss of $(1,133,000) for Q2 2025, compared to an income of $122,000 in Q2 2024 [5][22] - Net loss for Q2 2025 was $(1,238,000) or $(0.06) per share, compared to a net income of $30,000 or $0.00 per share in Q2 2024 [5][22] Business Highlights - Service and training revenue increased by 33% year-over-year in Q2 2025 and by 46% in the first half of 2025, indicating strong demand for decontamination services [5][6] - SteraMist solution sales rose by 40% year-over-year for the first half of 2025 [5] - The company achieved nearly 20% of Q2 revenue from international markets, demonstrating ongoing global expansion [5][6] Strategic Initiatives - The company is focused on expanding recurring service contracts and exploring new product lines to generate steady income [12] - Plans to strengthen the corporate team and expand talent in key areas such as sales and customer support are underway [9] - The company is negotiating approximately $2 million in new custom and integrated contracts, with bids expected to close before year-end [5] Leadership and Recognition - David Vanston was appointed as Chief Financial Officer in May 2025, bringing extensive experience to support growth and capital strategy [7] - The company received the "Disinfection and Decontamination Products Company of the Year" award by MedTech Outlook in June 2025, highlighting its commitment to excellence [6] Liquidity and Capital Access - As of June 30, 2025, the company had working capital of $2.8 million, with cash used in operations improving by over $1 million compared to the prior year [8] - The company completed a $435,000 convertible note financing in the first half of 2025 to support growth initiatives [8]